On Tuesday, BofA Securities expressed a positive outlook on Morgan Stanley (NYSE:MS) shares, raising the price target from $140.00 to $146.00 and maintaining a Buy rating. Currently trading at $128.64, the stock has demonstrated impressive momentum with a 31.36% return over the past six months.
The firm's analysts highlighted Morgan Stanley's robust performance in the third quarter of 2024, which has bolstered investor confidence in the company's growth potential. According to InvestingPro, three analysts have recently revised their earnings upward for the upcoming period, with analyst targets ranging from $104 to $155.
Morgan Stanley's shares closed the previous year on a high, driven by strong financial results in the third quarter. The company maintains a solid financial foundation, with InvestingPro data showing an impressive gross profit margin of 86.55% and a healthy current ratio of 2.17. BofA Securities analysts believe that the momentum for the stock will persist, supported by upward earnings per share revisions and increased capital flexibility.
These factors are seen as advantageous for Morgan Stanley's management as they strive to meet strategic goals. The company has demonstrated consistent shareholder returns, having raised its dividend for 11 consecutive years.
The targets set by the management include reaching a return on tangible common equity (ROTCE) of 20%, compared to the 17.4% estimated for the full year of 2024. Additionally, the company aims to achieve an efficiency ratio of 70%, an improvement from the current 72.2%, and a pre-tax margin of 30% in wealth management, up from 27.2%.
According to BofA Securities, Morgan Stanley is on track to meet these objectives by the end of 2026. However, they also suggest that a stronger revenue growth environment could potentially accelerate this timeline. The firm's forecast is based on the premise that Morgan Stanley will continue to exhibit strong performance and meet its strategic financial goals within the specified timeframe.
In other recent news, Morgan Stanley reported strong third-quarter earnings with revenues hitting $15.4 billion and a net income of $3 billion, surpassing analysts' projections. The company also announced significant changes to its board with Stephen Luczo resigning and CEO Edward Pick taking on the additional role of Chairman from January 1, 2025. Morgan Stanley Capital Partners (WA:CPAP) (MSCP) has agreed to acquire Prescott's, a healthcare-focused clinical engineering services provider, and sell Sila Services to Goldman Sachs (NYSE:GS) Alternatives' Private Equity business.
Analysts have varied views on Morgan Stanley's stock. HSBC downgraded the stock to Hold, citing a balanced risk-reward at the current market valuation, while BofA Securities and Evercore ISI maintained positive ratings, raising their price targets. Citi also increased its price target, but retained a Neutral stance, suggesting more attractive opportunities elsewhere in the market.
These recent developments underscore Morgan Stanley's strategic investment capabilities and its commitment to both the healthcare and business services sectors. The company's strong earnings and revenue results, as well as the changes in its board and the recent acquisitions and sales, are all part of Morgan Stanley's ongoing operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.